Search
semorinemab (binds MAP-tau)
Indications:
- investigational treatment of Alzheimer's disease
Adverse effects:
- well tolerated [2]
Clinical trials:
- Lariat double-bind, placebo-controlled phase II trial reported reduced rate of cognitive decline with semorinemab at 49 weeks, but no benefit for functional decline [1]
- semorinemab does not slow clinical progression of Alzheimer's disease [2]
Mechanism of action:
- binds N-terminal part of microtubule-associated protein tau (MAP-tau)
Interactions
drug adverse effects of anti-Alzheimer monoclonal antibody
Related
investigational therapies for treatment of Alzheimer's disease
General
anti-Alzheimer monoclonal antibody
References
- AC Immune
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting
Monoclonal Antibody in Alzheimer's Disease.
https://ir.acimmune.com/news-releases/news-release-details/ac-immune-announces-first-positive-cognitive-results-tau
- Teng E, Manser PT, Pickhorn K et al
Safety and Efficacy of Semorinemab in Individuals With Prodromal to
Mild Alzheimer Disease. A Randomized Clinical Trial.
JAMA Neurol. Published online June 13, 2022
PMID: 35696185
https://jamanetwork.com/journals/jamaneurology/fullarticle/2793069